2025-524728-22-01Not yet recruitingPhase 1/2
ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Jun 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 16 Apr 2026
- Start date
- 1 Jun 2026
- Lead sponsor
- Assistance Publique Hopitaux De Paris
- Diseases
- Acute myeloid leukemia
- EU CT number
- 2025-524728-22-01
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 36
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assistance Publique Hopitaux De Paris | Bobigny | France | Not yet recruiting |
| Institut Paoli-Calmettes | Marseille | France | Not yet recruiting |
| Centre Hospitalier Universitaire de Nice | Nice | France | Not yet recruiting |
| Assistance Publique Hopitaux de Paris | Paris | France | Not yet recruiting |
| Institut Gustave Roussy | Villejuif Cedex | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.